Abstract: Compositions and methods are provided for detection, diagnosis and prognosis of Lyme disease (LD), including a method for confirming Borrelia spp. infection by contacting, in vitro, whole blood samples from subjects suspected of having LD with synthetic peptides comprising T-cell epitope-containing regions derived from Borrelia proteins that are expressed at different stages of Lyme disease, and indirectly detecting LD-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-Y) in response to stimulation by the peptides.
Type:
Grant
Filed:
March 12, 2021
Date of Patent:
August 20, 2024
Assignees:
QIAGEN Sciences LLC, Biopeptides Corp., Gundersen Lutheran Medical Foundation, Inc.
Inventors:
Steven M. Callister, Jeff Boyle, Misato Miyamasu, Raymond Dattwyler, Paul M. Arnaboldi
Abstract: Compositions and methods are provided for detection, diagnosis and prognosis of Lyme disease (LD), including a method for confirming Borrelia spp. infection by contacting, in vitro, whole blood samples from subjects suspected of having LD with synthetic peptides comprising T-cell epitope-containing regions derived from Borrelia proteins that are expressed at different stages of Lyme disease, and indirectly detecting LD-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-Y) in response to stimulation by the peptides.
Type:
Grant
Filed:
September 15, 2016
Date of Patent:
April 20, 2021
Assignees:
QIAGEN Sciences LLC, Biopeptides Corp., Gundersen Lutheran Medical Foundation, Inc.
Inventors:
Steven M. Callister, Jeff Boyle, Misato Miyamasu, Raymond Dattwyler, Paul M. Arnaboldi
Abstract: The present invention relates, e.g., to a composition comprising peptides represented by SEQ ID NO:1, or active variants thereof, wherein the peptides or active variants can bind specifically to an antibody induced by a causative agent of Lyme disease (a pathogenic Borrelia), e.g. in a sample from a subject having Lyme disease. Compositions of the invention may comprise multiple peptides, from multiple proteins. Diagnostic kits comprising the peptides are described, as are diagnostic assays using the peptides.
Type:
Application
Filed:
December 8, 2014
Publication date:
October 27, 2016
Applicant:
BIOPEPTIDES CORP.
Inventors:
Raymond J. DATTWYLER, Paul M. ARNABOLDI
Abstract: The present invention relates, e.g., to a Lactobacillus bacterium, which (1) expresses a recombinant polypeptide containing a lipoprotein signal sequence from the OspA protein of Borrelia burgdorferi, or an active variant of the leader sequence, operably linked to one or more heterologous polypeptide(s) of interest and/or (2) which comprises an expressible polynucleotide encoding a recombinant polypeptide, wherein the polynucleotide encodes a lipoprotein signal from the OspA protein of Borrelia burgdorferi, or an active variant thereof, which is operably linked to one or more heterologous polypeptide(s) of interest. In one embodiment, the heterologous polypeptide is from Yersinia pestis, the etiologic agent of plague. In another embodiment, the heterologous polypeptide is from Borrelia burgdorferi, the etiologic agent of Lyme disease.
Type:
Application
Filed:
June 12, 2006
Publication date:
December 31, 2009
Applicants:
Biopeptides Corp., Lactrys Octrooi BV
Inventors:
Raymond J. Dattwyler, Maria J.C. Gomes-Solecki, Jozef F.M.L. Seegers